Stem cells and cancer: An introduction

Stem Cells and Cancer

Volumn , Issue , 2009, Pages 1-31

  Sell, Stewart ^a  

^a WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80051699029     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-89611-3_1     Document Type: Chapter

References (138)

1. Adami GA. The Principles of Pathology. Henry Frowde, London, 1909.
2. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res 2008;68:4018-4021.
3. Al-Hajj M,WichaMS, Benito-Hernandez A,Morrison SJ, Clarke MR. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100: 3983-3988.
4. Arnold I, Watt FM. c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol 2001;1:558-568.
5. Aterman KJ. The stem cells of the liver - a selective review. Cancer Clin Oncol 1992;118:87-115.
6. Bainbridge WS. The Cancer Problem. Macmillan, New York, 1914.
7. Baird SM. Hepatopoietic stem cells in leukemia and lymphoma. In Sell S (Ed) Stem Cells Handbook. Humana Press, Totowa, NJ, 2004, pp 163-175.
8. Bannasch P. Sequential cellular changes during chemical carcinogenesis. J Cancer Res Clin Oncol 1984;108:11-22.
9. Becker AJ, McCulloch E, Till J. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963;197:452.
10. Benecke BW. Zeigler's Beitruge zur Path. Anat., 1892-1893.
11. Berenblum I. The mechanism of carcinogenesis. A study of the significance of cocarcinogenic action and related phenomena. Cancer Res 1941;1:807. AN AACR SCIENTIFIC LANDMARK.
12. Berenblum I. Carcinogenesis and tumor pathogenesis. Adv Cancer Res 1954;2:129-175.
13. Berenblum I, Shubik P. A new quantitative approach to the study of the stages of chemical carcinogenesis in the mouse's skin. Br J Cancer 1947;1:384-391.
14. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
15. Borrel A. Le probleme du cancer. Bull Inst Pasteur 1907;5:497-512, 545, 593-608, 642-662.
16. Boutwell RK. Some biological aspects of skin carcinogenesis. Prog Exp Tumor Res 1964;4:207-250.
17. Boveri R. Zur frage der entstehung maligner tumoren. Fischer, Jena, 1914. AN AACR SCIENTIFIC LANDMARK.
18. Brown K, Strathdee D, Bryson S, Lambie W, Balmain A. The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted. Curr Biol 1998;8:516-514.
19. Buick RN. In vitro clonogenicity of primary human tumor cells: quantitation and relationship to tumor stem cells. In Salmon S (Ed) Cloning of Humor Tumor Stem Cells. AR Liss, New York, 1980, pp 15-20, Chapter 2.
20. Camacho LY. Clinical application of retinoids in cancer medicine. J Biol Regul Homeost Agents 2003:17:98-114.
21. Chalandon Y, Schwaller J. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. Haematologica 2005;90:949-968.
22. Chan DW, Sell S. Tumor markers. In Burtis CA, Ashwood ER (Eds) Tietez Textbook of Clinical Chemistry, 5nd Edn. Saunders, Philadelphia, 2001, pp 390-413.
23. Cho RW, Wang X, Diehn M, Shedden K, Chen CY, Sherlock G, Gurney A, Lewicki J, Clarke MF. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 1998;26:364-371.
24. Cohnheim J. Congenitales, quergestreiftes muskelsarkon der nireren. Virchows Arch 1875;65:64.
25. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 1999;59(7 Suppl):1685 s-1692 s.
26. Denekamp J. Tumour stem cells: facts, interpretation and consequences. Radiother Oncol 1994;30:6-10.
27. Dreesen O, Brivanlou AH. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 2007;3:7-17.
28. Druker BJ, Ralpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian J, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;334:1031-1037. AN AACR SCIENTIFIC LANDMARK.
29. Druker BJ, Cuilhot F, O'Brien SG, et al. Five year follow-up of patients receiving Imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
30. Durante F. Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. Arch Memor Osser Chir Pract 1874;11:217-226.
31. Fang AF, Ngai P, Ho DW, Yu WC, Ng NP, Lau CK, Li LY, Tam KO, Lam CT, Poon TP, Fan ST. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008;47:919-928.
32. Farber E. Similarities in the sequence of early histologic changes induced in the livers by ethionine, 2-acetylaminofluorene and 30-methyl-4-dimethylaminoazobenzene. Cancer Res 1956;16:142-148.
33. Farber E. Ethionine carcinogenesis. Adv Cancer Res 1963;7:383-474.
34. Farnie G. Clarke RB. Mammary stem cells and breast cancer-role of Notch signaling. Stem Cell Rev 2007;3:169-175.
35. Friedwald WF, Rous P. The initiating and promoting elements in tumor production. An analysis of the effects of tar, benzpyrene and methylcholanthrene on rabbit skin. J Exp Med 1944;80:101-126.
36. Furth J, Kahn MC. The transmission of leukemia of mice with a single cell. Am J Cancer 1937;31:276-282. AN AACR SCIENTIFIC LANDMARK.
37. Garland AM. Human papillomavirus update with a particular focus on cervical disease. Pathology 2002;34:213-224.
38. Glinsky G. Genomic models of metastatic cancer. Cell Cycle 2006;5:11-23.
39. Goldblatt H, Cameron G. Induce malignancy in cells from rat myocardium subjected to intermittent anaerobiosis during long propagation in vitro. J Exp Med 1954;97: 525-562.
40. Goldblatt H, Lynch J, Nangal RG, Summerville WW. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934;59:347-379.
41. Green HSN. The significance of the heterologous transplantibility of human cancer. Cancer 1952;5:24-44.
42. Haas R, Muczynski KA, Krailo M, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer 1989;64:1082-1095.
43. Hewitt HB. Transplantation of mouse sarcomas with small numbers of single cells. Nature 1952;170:622-623.
44. Hill RP, Perris R. "Destemming cancer stem cells". J Natl Cancer Inst 2007;99:1435-1340.
45. Ilmmenesee K. Reversion of malignancy and normalized differentiation of teratocarcinoma cells in mammals. In Russel LC (Ed) Generic Mosaics and Chimeras in Mammals. Plenum, New York, 1978, pp 3-25.
46. Ivanova N, Dobrin R, Lu R, Kotenko I, Levorse J, DeCoste C, Schafer X, Lun Y, Lemischka IR. Dissecting self-renewal in stem cells withRNAinterference. Nature 2006;442:533-538.
47. Kaposi-Novak P, Lee J-S, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgerisson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582-1595.
48. Kasai M, Watanabe I. Histologic classification of liver cell carcinoma in infancy and childhood and its clinical evaluation. Cancer 1970;25:551-563.
49. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007;317:337.
50. Kern SE, Shibata D. The fuzzy math of solid tumor stem cells: a perspective. Cancer Res 2007;67:8985-8988.
51. Kovacs CJ, Evans MJ, Wakefield JA, Looney WB. A comparative study of the response to radiation by experimental tumors with markedly different growth characteristics. Radiat Res 1977;72:455-468.
52. Lapidot T, Sirard C, Bormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648.
53. Li C, Heidt DG, Dalerba PK, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007:67:1030-1037.
54. Liao M-J, Zhang CC, Zhou B, et al. Enrichment of a population of mammary gland cells that formmammospheres and have in vivo repopulating activity. Cancer Res 2007;67:8131-8138.
55. Looney WB, Mayo AA, Janners MY, et al. Cell proliferation and tumor growth in hepatoma 3924A. Cancer Res 1971;31:821-825.
56. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556.
57. Ma S, Lee TK, Zheng B-J, Chan KW, Guan X-Y. Cd133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749-1758.
58. Makino S, Kano K. Cytologic studies of tumors, XIV. Isolation of single-cell clones from a mixed-cell tumor of the rat. J Natl Cancer Inst 1955;15:1165-1181.
59. McCulloch EA. Normal and leukemic hematopoietic stem cells and lineages. In Sell S (Ed) Stem Cells Handbook. Humana Press, Totowa, NJ, 2004, pp 119-131.
60. Melnick A, Licht JD. Deconstructing a disease: RARa, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-3215.
61. Mintz B, Illmmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA 1975;72:3583-3589.
62. Morris HP, Meranze DR. Induction and some characteristics of "minimal deviation" and other transplantable rat hepatomas. Recent Results Cancer Res 1974;44:103-111.
63. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89:213-238.
64. Nowell PC. Diagnostic and prognostic value of chromosome studies in cancer. Ann Clin Lab Sci 1974;4:234-240. AN AACR SCIENTIFIC LANDMARK.
65. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-28.
66. O'Hare MJ. Teratomas, neoplasia and differentiation: a biological overview I. The natural history of teratomas. Invest Cell Pathol 1978;1:39-63.
67. Owens DM, Watt FM. Contribution of stem cells and differentiated cells to epidermal tumors. Nat Rev Cancer 2003;3:444-451.
68. Paget J. Lectures on surgical Pathology. London, 1853
69. Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC 3rd, Janz S. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res 2005;65:1306-1315.
70. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999;3:565-577.
71. Perez-Losada J, Balmain A. Stem cell hierarchy in skin cancer. Nat Rev Cancer 2003;3:434-443.
72. Pierce GB, Dixon FJ. The demonstration of teratogenesis by metamorphosis of multipotential cells. Cancer 1959;12:573-583.
73. Pierce GB, Spears WC. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988;48:1196-1204.
74. Pierce GB, Wallace C. Differentiation of malignant to benign cells. Cancer Res 1971;31:127-134. AN AACR SCIENTIFIC LANDMARK.
75. Pierce GM, Dixon FJ, Verney E. Teratocarcinogenic and tissue forming potentials of the cell types comprising neoplastic embryoid bodies. Lab Invest 1960;9:583-602.
76. Pierce GB, Shikes R, Fink LM. Cancer: A Problem of Developmental Biology. Prentice Hall Inc., Engelwood Cliffs, NJ, 1978, pp 1-242.
77. Pirollo KF, Chang EH. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res 2008;68:1247-1250.
78. Pirollo KF, Rait A, Zhou Z, Hwang SH, Dagata JA, Zon G, et al. Materializing the potential of small interfering RNA via tumor-targeting nanodelivery system. Cancer Res 2007;67:2938-2943.
79. Pott P. Chirurgical Observations Relative to the Cataract, the Polypus of the Nose, the Cancer of the Scrotum, the Different Kinds of Ruptures, and the Mortification of the Toes and Feet. Hawes, Clarke and Colllins, London, 1775.
80. Potten CS, Morris RJ. Epithelial stem cells in vivo. J Cell Sci 1988;10(Suppl):45-62.
81. Potter M. Percivall Pott's contribution to cancer research. NCI Monogr 1963;10:1-13.
82. Prehn RT. The role of mutation in the new cancer paradigm. Cancer Cell Int 2005;5:9-13.
83. Puck TT, Marcus PI. A rapid method of viable cell titration and clone production with HeLa cells in tissue culture: use of x-irradiated cells to supply conditioning factors. PNAS 1955;41:432-437.
84. Puttini M, Coluccia ML, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against Imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006;66:11314-11322.
85. Recamier JCA. Recherches sur the traitement du cancer: par la compressionmethodique simple ou combinee, et sur l'histoire general de la meme maladie. 2 vols, Gabon, Paris, 1829.
86. Reinhard MC, Goltz HL, Warner SC. Further studies on the quantitative determination of the growth of a transplantable mouse adenocarcinoma. Cancer Res 1952a;5:102-106.
87. Reinhard MC, Goltz HL, Warner SG, Mirand EC. Growth rate and percentage takes following inoculation of known numbers of viable mouse tumor cells. Exp Med Surg 1952b;10:254.
88. Remak R. Ein beitrag zur entwickelungsgeschichte der krebshaften geschwulste. Deut Klin 1854;6:170-174.
89. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
90. Rich JN. Cancer stem cells in radiation resistance. Cancer Res 2007;67:8980-8984.
91. Rippert H. Geschwulstelehre fur Aerzte und Studierende. Bonn, 1904.
92. Rous P.A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med 1911;13:397-411. AN AACR SCIENTIFIC LANDMARK.
93. Rous P, Kidd JG. Conditional neoplasms and subthreshold neoplastic states. J Exp Med 1942;73:365-372.
94. Rowley JD. Nonrandom chromosomal abnormalities in hematologic disorders of man. Proc Natl Acad Sci USA 1975;72:152-156.
95. Rygaard J, Povlsen CO. Heterotransplantation of a human malignant tumour to "Nude"mice. Acta Pathol Microbiol Scand 1969;77:758-760. AN AACR SCIENTIFIC LANDMARK.
96. Salmon S. In vitro effects of drugs on human tumor stem cell assays. In Salmon S (Ed) Cloning of Human Tumor Stem Cells. AR Liss, New York, 1952, pp 197-312.
97. Sell S. Distribution of alphafetoprotein and albumin containing cells in the livers of Fischer rats fed four cycles of N-2-fluorenylacetamide. Cancer Res 1978;38:3107-3113.
98. Sell S. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology 2001;33:738-750.
99. Sell S. Stem cell origin of cancer and differentiation therapy. CR Oncol/Hematol 2004a;51:1-28.
100. Sell S. Stem cells. What are they? Where do they come from? Why are they here? When do they go wrong? Where are they going? In Sell S (Ed) Stem Cells Handbook. Humana Press, Totowa, NY, 2004b, pp 1-18.
101. Sell S. Leukemia: stem cells, maturation arrest and differentiation therapy. Stem Cell Rev. 2005;1:197-205.
102. Sell S. Potential gene therapy for cancer stem cells. Curr Gene Ther 2006a;6:579-591.
103. Sell S. Stem cells in hepatocarcinogenesis. Cell Sci Rev 2006b;3:302-341.
104. Sell S. Cancer stem cells and differentiation therapy. Tumor Biol 2006c;27:59-70.
105. Sell S. Cancer and stem cell signaling: a guide to preventive and therapeutic strategies for cancer stem cells. Stem Cell Rev 2007a;3:1-6.
106. Sell S (Ed). Cancer and stem cell signaling. Stem Cell Reviews, Vol 3. Humana Press, Totowa, NJ, 2007b, pp 1-103.
107. Sell S. Alpha-fetoprotein, stem cells, and cancer. The Abbot Award Lecture. Tumor Biol 2008;29:161-180.
108. Sell S. History of cancer stem cells. In Rajasekhar VK, VemuriM(Eds) Regulatory Networks in Stem Cells. Humana Press, Totowa, NJ, 2009, pp 495-504.
109. Sell S, Becker FF. Guest editorial: alpha-fetoprotein. J Natl Cancer Inst 1978;60:19-26.
110. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol 1989;134:1347-1363.
111. Sell S, Leffert HL. An evaluation of the cellular lineages in the pathogenesis of experimental hepatocellular carcinoma. Hepatology 1982;2:77-86.
112. Sell S, Pierce GB. Biology of disease: maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 1994;70:6-21. AN AACR SCIENTIFIC LANDMARK.
113. Sell S, Sala-Trepat J, Sargent T, Thomas K, Nahon J-L, Goodman T, Bonner J. Molecular mechanisms of control of albumin and alphafetoprotein production: a system to study the early effects of chemical hepatocarcinogens. Cell Biol Intl Rep 1980;4:235-254.
114. Shimkin M. Contrary to Nature. NIH, USDOH, 1977.
115. ShipitsinM,CampbellLL,Argani P,Weremowicz S, Bloushtain-QimronN,Yao J, Nikolskaya T, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11: 259-273.
116. Soignet S, Fleischauer A, Pollyak T, Heller G, Warrel Jr RP. All trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long term follow-up of the New York study. Cancer Chemother Pharmacol 1997;40:S24-S29.
117. Stevens LC. Experimental production of testicular teratomas in mice. Proc Natl Acad Sci USA 1964;52:654-661.
118. Stevens LC. Origin of testicular teratomas from primordial germ cells in mice. J Natl Cancer Inst 1967;38:549-552.
119. Stevens LC. The development of teratomas from intratesticular grafts of tubal mouse eggs. J Embryol Exp Morphol 1968;20:329-341.
120. Stevens LC. The development of transplantable teratocarcinomas from intratesticular grafts of pre- and post implantation mouse embryos. Dev Biol 1970;21:364-382.
121. Sutherland HJ, Blair A, Zapf RW. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 1996;87:4754-4761.
122. Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Lab Invest 2006;86:1203-1207.
123. Teebor GW, Becker FF. Regression and persistence of hyperplastic hepatic nodules induced by N-2-fluorenylacetamide and their relationship to hepatocarcinogenesis. Cancer Res 1971;31:1-3.
124. Thiersch C. Der epithelialkrebs namenlich der Haut. Eine anatomisch kliniche Untersuchung. Mit einen Atlas microscopischer Abbildungen. Lepiz, 1865.
125. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961;14:213-222.
126. Till JE, McCulloch EA, Siminovitch L.A stochastic model of stem cell proliferation, based on the growth of spleen colony forming cells. Proc Natl Acad Sci USA 1964;51:29-36.
127. Trott KR. Tumour stem cells: the biological concept and its application in cancer treatment. Radiother Oncol 1994;30:1-5.
128. Van Duuren BL, Sivak A, Katz C, Seidman I, Melchionne S. The effect of ageing and interval between primary and secondary treatment in two-stage carcinogenesis on mouse skin. Cancer Res 1975;35:502-505.
129. Virchow R. Dir Krankhoften Geschwulste. Berlin, 1863, vol II. Onkologie, Pt 1.
130. Waikel RL, Kawachi Y, Waikel PA, Wang XJ, Roop DR. Deregulated expression of c-Myc depletes epidermal stem cells. Nat Genet 2001;28:165-168.
131. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927;8:519-530.
132. Watt FM. Terminal differentiation of epidermal keratinocytes. Curr Opin Cell Biol 1989;1:1107-1115.
133. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006;66:1883-1890.
134. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budu A, Zanetti KA, Chen Y, Qin L-X, Tang Z-Y, Wang XW. EpCAM and a-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-1461.
135. Yan AF, Ho DW, Ng MN, Lau CK, Yu WC, Ngal P, Chu EK, Lan CT, Poon TP, Fan ST. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008;13:153-166.
136. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ce C, Xie H, Wan D, Yang S, Zheng S, Gu J. CD133 positive hematocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007;120:1444-1450.
137. Zen Y, Fujii T, Yoshikawa S, Takamura H, Tani T, Ohtia T, Nakanuma Y. Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol 2007;170:1750-1762.
138. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 2007; DOI 10.1007/s10549-007-9798-y.